Showing results (71-80 of 91) with videos related to
Sort By:
Pageof 10
Brain Research Bulletin|January 1, 1996
Electrically induced fos-like immunoreactivity in the auditory pathway of the rat: effects of survival time, duration, and intensity of stimulationJ S Zhang, C A Haenggeli, A Tempini, et al.British Journal of Cancer|March 10, 1999
Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancerM M Borner, P Brousset, B Pfanner-Meyer, et al.Respiration Physiology|October 1, 1980
Comparison of steady state pulmonary diffusing capacity estimates for O2 and CO in dogsJ Savoy, M C Michoud, M Robert, et al.Leukemia & Lymphoma|October 24, 2000
Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemiaT Pabst, U R Peters, M Tinguely, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 1998
Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK)D C Betticher, D Ratschiller, S F Hsu Schmitz, et al.Oncogene|December 5, 1998
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpressionS Vonlanthen, J Heighway, M P Tschan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphomaD C Betticher, A von Rohr, D Ratschiller, et al.Cancer Letters|April 24, 2007
Origin and prognostic value of circulating KRAS mutations in lung cancer patientsO Gautschi, B Huegli, A Ziegler, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trialR Rosell, U Gatzemeier, D C Betticher, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2007
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03G D'Addario, D Rauch, R Stupp, et al.Pageof 10